12-and 24-Week Patient-Reported Outcomes from a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis Chalabi, Y., Smolen, J., Taylor, P., Genovese, M., Lee, C., Schlichting, D., Macias, W., Keystone, E. J RHEUMATOL PUBL CO. 2014: 1498–99

View details for Web of Science ID 000338923700148